🔎 Trials Near Me

Beranda › Fibrosis Paru Idiopatik › California

Uji klinis Fibrosis Paru Idiopatik di California

13 studi untuk Fibrosis Paru Idiopatik mencari peserta di lokasi di California.

Kota di California

Teks studi resmi (Bahasa Inggris)

Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring

  • University of California, San Francisco, San Francisco
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT07673237

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  • University of Southern California, Los Angeles
  • Newport Native MD, Inc., Newport Beach
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06951217

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

  • Research Site, Loma Linda
  • Research Site, Los Angeles
  • Research Site, Newport Beach
  • dan 2 lainnya
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 21 Sep 2026 · NCT07652658

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

  • Kadima Neuropsychiatry Institute, San Diego
  • Providence Medical Foundation, Santa Rosa
Menerima pesertaFase 2
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT07002034

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

  • Newportnativemd, Inc., Newport Beach
  • Palmtree Clinical Research, Palm Springs
  • Paradigm Clinical Research Centers, Inc. - Redding, Redding
Menerima pesertaFase 3
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT07671911

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

  • University of Southern California, Los Angeles
  • Cedars Sinai Medical Center, Los Angeles
  • Paradigm Clinical Research Centers, LLC, San Diego
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06968845

Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  • Palmtree Clinical Research Inc., Palm Spring
  • Paradigm Clinical Research Centers LLC, Redding
Menerima pesertaFase 3
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07284602

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  • University of California San Francisco, San Francisco
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT05571059

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

  • University of California - Los Angeles, Los Angeles
  • University of Southern California, Los Angeles
  • Stanford University, Stanford
Menerima pesertaStudi observasional
Usia 21 ke atas · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT01915511

Dose-Escalation Study of Artesunate Patients With IPF

  • Stanford University, Stanford
Menerima pesertaFase 1
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT05988463

WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

  • WISPer Site in Los Angeles, CA, Los Angeles
  • WISPer site in Newport Beach, CA, Newport Beach
  • WISPer Site in Palm Springs, CA, Palm Springs
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT06967805

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

  • Keck School of Medicine of USC, Los Angeles
Menerima pesertaFase 2
Usia 40 ke atas · Semua jenis kelamin · Diperbarui 12 Nov 2025 · NCT05975983

Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis

  • Cedars-Sinai, Los Angeles
Menerima pesertaFase 2
Usia 50 ke atas · Semua jenis kelamin · Diperbarui 10 Nov 2025 · NCT06567717

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.